(HealthDay News) — Use of a computerized clinical decision support system (CDSS) may reduce the risk of prolonged QT c interval in hospitalized patients at risk for torsades de pointes, according to ...

For many years, moderate alcohol intake and its effect on health have been subject to much debate, particularly concerning cardiovascular health. Indeed, light-to-moderate use of alcohol has been ...

Boston, MA - Patients who receive high doses of the antidepressants citalopram or escitalopram could potentially develop QT-interval prolongation, a marker of a slight increased risk for ventricular ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Drugs that prolong the QT interval may increase the risk ...

SAN DIEGO, INDIANAPOLIS, and WALTHAM, Mass., July 7, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today ...

Long QT syndrome is a leading cause of sudden death in young persons, with a prevalence exceeding 1 in 2000. It is characterized by prolongation of the QT interval, aberrant T-wave morphologic ...

Tyrosine kinase inhibitors (TKIs) are associated with prolongation of the QTc interval on the electrocardiogram (ECG). The QTc-interval prolongation increases the risk of life-threatening arrhythmias.

Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma Investigation and utilization of molecularly targeted agents has induced a number of drug ...

Please provide your email address to receive an email when new articles are posted on . Compared with married people, unmarried people were more likely to have a prolonged QT interval, according to ...

Results to be Included in BYDUREON™ New Drug Application Resubmission in the Third Quarter of 2011 SAN DIEGO & INDIANAPOLIS & WALTHAM, Mass.--(BUSINESS WIRE)-- Amylin Pharmaceuticals, Inc. (Nasdaq: ...

Results to be Included in BYDUREON TM New Drug Application Resubmission in the Third Quarter of 2011 SAN DIEGO & INDIANAPOLIS & WALTHAM, Mass.--(BUSINESS WIRE)--Amylin Pharmaceuticals, Inc. (Nasdaq: ...